SSP Holdings
ADDRecommended as a strong buy at 136.5p last month, shares in SSP Holdings have skipped 16 per cent higher on news of an approach, and remain compelling fare based on further bid excitement as well as the group’s attractions as an independent.
Following upwards momentum in the share price, the largest provider of software and services to the UK general insurance sector confirmed it is in early-stage discussions with a financial buyer, which, in well-worn form, ‘may or may not lead to an offer being made for the company’.
The predator in question is no doubt attracted to the various merits of the business that we highlighted not long ago. Namely, it provides ‘business-critical’ systems to insurers and insurance intermediaries, with its client roster including the likes of Fortis Insurance, Norwich Union and Swinton. Moreover, its high-margin and highly cash-generative revenue model is a source of strength, combining subscription licence fees, transaction fees and long-term managed service contracts, lending the company a high proportion of recurring revenue and high earnings visibility.
Even if a bid fails to materialise, SSP is a superior business worth backing for the long-term, with its exposure to the cash-rich general insurance market as well as industry consolidation playing into its hands.
Next month, SSP is forecast to unveil annual profits of £11.6m and 10.9p of earnings, from turnover of £63.2m, ahead of £15.6m and 13.6p for March 2009. Trading on forward earnings multiples of 14.5 and 11.6, the shares still look great value and investors might consider adding to existing holdings.
Growth Company Investor subscribers have full access to all our AIM and small-cap share recommendations. To subscribe today with a half-price offer, and gain immediate access to all the recommendations, click here.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £130.97m
PE Forecast: 14.5
Share price: 158.5p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
